On Friday, Brookdale Senior Living, Inc. (NYSE:BKD)’s shares declined -0.33% to $36.75.
Brookdale Senior Living, Inc. (BKD) declared that administration will take part in a talk about regarding the Company at the Goldman Sachs 36th Annual Healthcare Conference in Los Angeles, California on Tuesday, June 9, 2015, starting at 10:40 a.m. Pacific Time.
Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Ongoing Care Retirement Communities (CCRCs) Rental, Brookdale Ancillary Services, and Administration Services.
Constellium NV (NYSE:CSTM)’s shares dropped -3.41% to $13.60.
Constellium NV (CSTM) was aboard Orion’s successful first flight test, Exploration Flight Test-1 (EFT-1). Built by Lockheed Martin, NASA’s Orion spacecraft is designed for human exploration of deep space.
In 2010, after a two-year materials study by Lockheed Martin – AIRWARE® 2195 and 2050 low density alloys manufactured at Constellium’s facilities located in Ravenswood, West Virginia, USA and Montreuil-Juigne and Issoire, France, – were chosen as key structural materials of the Orion spacecraft based on their proven reliability and safety in space in the study.
The alloys’ inherent low density, high-specific stiffness, strength and excellent mechanical properties ensure material high-performance characteristics during demanding launch and landing phases, and at the same time, a lower density to facilitate the ascent to outer space, contributing to a successful EFT-1.
Constellium N.V. is engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products for the aerospace, packaging, and automotive end-markets. The company operates in three segments: Aerospace & Transportation, Packaging & Automotive Rolled Products, and Automotive Structures & Industry.
At the end of Friday’s trade, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)‘s shares surged 2.83% to $66.15.
ISIS Pharmaceuticals, Inc. (ISIS) declared that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Based on this approval, Bayer will pay Isis an immediate $100 million up-front payment. In total, Isis is eligible to receive up to $375 million in payments, counting the upfront payment and a $55 million near-term milestone payment upon advancement of the program following the Phase 2 study in patients with compromised kidney function. In addition, Isis is eligible to receive tiered royalties in the low to high twenty percent range on gross margins of ISIS-FXIRx. After completion of ongoing activities at Isis, Bayer will assume all global clinical development in addition to worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, counting cardiovascular and metabolic diseases; severe and rare diseases, which comprise neurological disorders; and cancer.
Atwood Oceanics, Inc. (NYSE:ATW), ended its Friday’s trading session with 0.20% gain, and closed at $29.93.
Atwood Oceanics, Inc. (ATW) declared recently that Mark L. Mey has resigned from his position as Executive Vice President and Chief Financial Officer of the Company to pursue other interests.
Rob Saltiel, President and Chief Executive Officer of Atwood, remarked, “Mark has played a noteworthy role in the Company`s growth strategy over the past five years, and we are sorry to see him leave.”
The Board of Directors has designated Mark W. Smith as Chief Financial Officer on an interim basis. Mr. Smith has served as Vice President, Chief Accounting Officer and Controller since May 2014 and in other finance roles since joining the Company in February 2009. Counting his service to the Company, Mr. Smith has over 20 years` experience in the financial, consulting and energy industries.
Atwood Oceanics, Inc., an offshore drilling contractor, engages in the drilling and completion of exploratory and developmental oil and gas wells worldwide. As of November 10, 2014, it owned a fleet of 13 mobile offshore drilling units, in addition to 3 ultra-deepwater drill ships under construction. The company was founded in 1968 and is headquartered in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.